Two meta-analyses comparing the pulmonary safety of anti-PD-1 and anti-PD-L1 showed that anti-PD-1 monoclonal antibodies led to a higher incidence of pneumonia than anti-PD-L1 monoclonal antibodies [35]. Here, CD274 is linked to pneumonia.